Sep 2026· Annals of Clinical and Translational Neurology· 0 citations· 33 references
Medicine
TL;DR
Rising sNfL may precede mobility decline, highlighting sNfL as a potential indicator of functional worsening, and lower sNfL was associated with reduced daily ambulatory activity in progressive MS.
Abstract
ABSTRACT Objective Neurofilament light chain (NfL) is a biomarker of neuroaxonal injury in multiple sclerosis (MS), yet associations with functional outcomes remain unclear. Longitudinal associations between serum NfL (sNfL) and daily step count (STEPS) from wearable devices were assessed in a large international progressive MS cohort. Methods A post hoc analysis of the Phase III randomized controlled trial SPI2 (high‐dose biotin vs. placebo RCT) pooled treatment arms due to no observed therapeutic benefit. Participants with sNfL and step count data were included. STEPS were calculated within ±15‐days of baseline, 6, 12, 15, and 27‐month visits. Mixed‐effects models with 1000 bootstrap iterations assessed contemporaneous associations with each measure alternately specified as the outcome, adjusting for age and sex. Lagged models evaluated whether 0–6‐month sNFL changes predicted subsequent 6–12‐month STEPS changes. Results Among 506 participants (53.8% female; mean age 52.7 [SD: 7.7] years; median EDSS 6.0 [4.5–6.0]), mean sNfL z‐score was 1.00 (SD: 0.95), and median STEPS were 3029 [1708–5210]. Higher sNfL was associated with lower STEPS (IRR = 0.97, p = 0.014), consistent across sex, treatment, disability, and disease‐modifying treatment status. Conversely, higher STEPS were associated with lower sNfL z‐scores; a 10% increase in STEPS corresponded to a 0.015 decrease in sNfL z‐score (95% CI −0.022 to −0.008; p < 0.001). Greater prior 6‐month increases in sNfL were associated with a lower subsequent STEPS (β = −141; 95% CI −302 to 21; p = 0.088; trend), corresponding to 141 fewer steps per 1‐SD sNfL increase. Interpretation Higher sNfL was associated with reduced daily ambulatory activity in progressive MS, and vice versa. Rising sNfL may precede mobility decline, highlighting sNfL as a potential indicator of functional worsening. Trial Registration ClinicalTrials.gov NCT02936037; EudraCT database 2016‐000700‐29
Abstract Objectives Serum neurofilament light chain (sNfL) reflects neuroaxonal injury in relapsing-remitting multiple sclerosis (RRMS), but its clinical utility is limited by high interindividual variability and confounders such as renal function. Population-based thresholds may therefore be suboptimal for longitudina...
S. de las Heras Flórez, Gema García de la Rosa, Vicente Martín García et al.· Clinical Chemistry and Labor...· 1 citation
Early repeated NFL measurements summarized as cuNFL and longitudinal trajectory groups were associated with short-term adverse events in this cohort, and support further external validation of longitudinal NFL-based risk stratification.
Jiahui Zhu, Yue-Chen Zhang, Bing-Jie Yang et al.· Neurobiology of Disease· 0 citations
To compare chronological age and neurofilament light chain (NfL)-derived age in people with multiple sclerosis (pwMS) and controls, and to explore clinical correlates of the NfL age gap. We conducted a real-world, retrospective analysis including 792 pwMS (without evidence of clinical or MRI activity in the previous ye...
Valerio Nicolella, Carmela Polito, Vincenzo Criscuolo et al.· Journal of Neurology· 0 citations
Failure to reduce zNfL levels after 1 year of treatment was associated with subsequent disease activity, even in patients otherwise considered stable, providing complementary information to clinical and MRI-based monitoring.
Victoria Fernández, A. Pappolla, P. Carbonell-Mirabent et al.· Neurology· 1 citation
Serum neurofilament light chain (sNfL) is a blood biomarker of neuroaxonal injury, but its early longitudinal dynamics and prognostic value in clinically heterogeneous acute stroke populations remain insufficiently defined. This study characterized early sNfL changes and examined their association with functional o...
Guang-Yong Chen, Yu-Xin Zhu, Feng Chen et al.· Frontiers in Neurology· 0 citations
This work assessed whether ECLIA NfL correlates with the ALSFRS‐R decline rate under the sampling conditions of clinical practice, and whether GFAP or S‐100B adds prognostic or disease‐specific information.
N. Streicher· Muscle and Nerve· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.